drugset
drugset / Trial / NCT01474681

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

NCT01474681 ↗

Phase 1/2 Completed 27 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.

Timeline

Start
2012-01-09
Primary completion
2016-10-03
Completion
2016-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HSC835 Cell therapy — —

Indications

Burkitt lymphoma acute myeloid leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myeloid leukemia follicular lymphoma lymphoblastic lymphoma lymphoplasmacytic lymphoma mantle cell lymphoma marginal zone lymphoma myelodysplastic syndrome